Company intelligence / Profile preview

Clearside Biomedical

Alpharetta, Georgia, United Statesclearsidebio.com ↗

Ownership: Public · CLSD
Employees: ~32
Development stage: Phase 3

Overview

Clearside has FDA approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use. Their lead program CLS-AX (axitinib injectable suspension) for wet AMD is advancing to Phase 3 clinical trials.

Therapeutic areas: OphthalmologyOncologyEndocrinology
Modalities: Small moleculesinjectable suspensions
Industry: Biotech

Drug pipeline

6 assets

CLS-AX

5 more assets in the full pipeline.

Request access →

Partnerships

Bausch + Lomb Ireland LimitedArctic Vision (Hong Kong) LimitedREGENXBIO, Inc.BioCryst Pharmaceuticals, Inc.Aura Biosciences, Inc.

Financials

Market cap: $2.1M
Total revenue: $201K
Enterprise value: $-4.2M

Beyond the preview

Go deeper on Clearside Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clearside Biomedical.

Explore the full profile